NASDAQ · NXGLWHealthcareSurgical Instruments

NexGel, Inc Warrant financials

$0.0122−1.61%
Close Sep 28, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$11.4M$8.7M$4.1M$2.0M$1.6M
Gross profit$4.5M$2.7M$374.0K$256.0K$8.0K
Gross margin39.5%31.6%9.1%12.5%0.5%
Operating income-$3.4M-$3.6M-$3.5M-$3.3M-$2.6M
Net income-$3.0M-$3.3M-$3.2M-$4.7M-$4.3M
Net margin−26.3%−37.8%−77.2%−231.7%−277.9%
Diluted EPS$-0.38$-0.50$-0.56$-0.85$-1.45
EBITDA-$2.9M-$3.1M-$3.0M-$3.0M-$2.5M
Operating cash flow-$1.3M-$3.9M-$3.2M-$3.0M-$2.8M
Free cash flow-$1.4M-$4.3M-$3.9M-$3.1M-$3.0M
Diluted shares7.9M6.5M5.7M5.6M3.0M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$317.0K$1.8M$2.7M$1.1M$13.3M
Short-term investments$0.00$0.00$0.00$5.5M$0.00
Total debt$406.0K$1.1M$593.0K$283.0K$2.3M
Total assets$10.5M$11.0M$10.0M$10.4M$17.0M
Total liabilities$5.6M$4.9M$4.8M$2.7M$4.9M
Shareholders' equity$4.9M$6.1M$5.2M$7.6M$12.1M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology